Gefitinib, one of the EGFR tyrosine kinase inhibitors (EGFR-TKIs), has been used for the treatment of advanced NSCLC patients with EGFR-activating mutations and has preferably achieved a superior survival benefit for these patients [4, 5]. Here, EGFR is linked to non-small cell lung carcinoma.